Federated Hermes’s OnKure Therapeutics OKUR Stock Holding History

Federated Hermes’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-65	Closed	-$1.03K	–	2150
2023 Q4	$1.03K	Sell	65 -5,945	-99%	-$370K	﹤0.01%	1972
2023 Q3	$458K	Sell	6,010 -27	-0.4%	-$1.84K	﹤0.01%	1367
2023 Q2	$396K	Sell	6,037 -1,802	-23%	-$145K	﹤0.01%	1438
2023 Q1	$469K	Sell	7,839 -161	-2%	-$5.83K	﹤0.01%	1418
2022 Q4	$186K	Buy	8,000 +5,000	+167%	+$133K	﹤0.01%	1568
2022 Q3	$101K	Hold	3,000	–	–	﹤0.01%	1609
2022 Q2	$80K	Buy	3,000 +1,300	+76%	+$30.3K	﹤0.01%	1631
2022 Q1	$50K	Hold	1,700	–	–	﹤0.01%	1739
2021 Q4	$145K	Hold	1,700	–	–	﹤0.01%	1671
2021 Q3	$127K	Hold	1,700	–	–	﹤0.01%	1744
2021 Q2	$159K	Buy	+1,700	New	+$190K	﹤0.01%	1719

Other funds holding OKUR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Federated Hermes's OKUR Position: Q1 2024 in Review

Federated Hermes sold out of OnKure Therapeutics (OKUR) in Q1 2024, closing a stake of 65 shares — an estimated $1.03K sold.

Federated Hermes first reported a position in OKUR in Q2 2021 and held it in 11 quarters. The position peaked at $469K in Q1 2023. 61 funds tracked by Wall St. Rank hold OKUR as of Q1 2024.

Federated Hermes reported no remaining OnKure Therapeutics position as of Q1 2024 after selling out during the quarter.
Federated Hermes sold 65 OnKure Therapeutics shares in Q1 2024, an estimated $1.03K.
Federated Hermes first reported a position in OnKure Therapeutics in Q2 2021 and held it in 11 quarters.
Federated Hermes's OnKure Therapeutics position peaked at $469K in Q1 2023.
61 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2024.

Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.